

# ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE (O.A.P.I.)

(19)



(11) N°

**11520**

(51) Inter. Cl. 7

C12N 15/67, 15/30, 5/10, 1/21  
C07K 14/445  
A01K 67/027  
A61K 48/00

**BREVET D'INVENTION**

(21) Numéro de dépôt :

(22) Date de dépôt :

(30) Priorité(s) :

(24) Délivré le : 13.08.2001

(45) Publié le : **09 FEV 2004**

(73) Titulaire(s) :

Société dite : GENZYME TRANSGENICS  
CORPORATION  
175 Crossing Boulevard  
FRAMINGHAM  
Massachusetts 01701-9322 (US)


(72) Inventeur(s) :

1- CHEN Li How  
12 Wachuset Drive  
ACTON, Massachusetts 01720  
(US)  
2- MEADE HARRY (US)

(74) Mandataire : CABINET CAZENAVE  
B.P. 500  
YAOUNDE - Cameroun

(54) Titre : Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.

(57) Abrégé : The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of malarial surface protein MSP-1 which is known to be difficult to express in cell culture systems, mammalian cell culture systems, or in transgenic animals. The preferred protein candidates for expression using the recombinant techniques of the invention are MSP-1 proteins expressed from DNA coding sequences comprising reduced overall AT content or AT rich regions and/or mRNA instability motifs and/or rare codons relative to the native MSP-1 gene.



Western Analysis of MSP transgenic milk.  
Lane 1, Molecular weight marker; lane 2, nontransgenic milk; lane 3, milk from  
BC65A-146 transgenic mouse; lane 4-9, milk from BC670 transgenic mice. The blot was  
reacted with monoclonal antibody 5.2 against MSP.

NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES  
AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN  
EXPRESSION IN CELL SYSTEMS

5

BACKGROUND OF THE INVENTION

10 Field of the invention

The invention relates to heterologous gene expression. More particularly, the invention relates to the expression of malaria genes in higher eukaryote cell systems.

15 Summary of the related art

Recombinant production of certain heterologous gene products is often difficult in *in vitro* cell culture systems or *in vivo* recombinant production systems. For example, many researchers have found it difficult to express proteins derived from bacteria, parasites and virus in cell culture systems different from the cell from which the protein was originally derived, and particularly in mammalian cell culture systems. One example of a therapeutically important protein which has been difficult to produce by mammalian cells is the malaria merozoite surface protein (MSP-1).

25 Malaria is a serious health problem in tropical countries. Resistance to existing drugs is fast developing and a vaccine is urgently needed. Of the number of antigens that get expressed during the life cycle of *P. falciparum*, MSP-1 is the most extensively studied and promises to be the most successful candidate for vaccination. Individuals exposed to *P. falciparum* develop antibodies against MSP-1, and studies have shown that there is a correlation between a naturally acquired immune response to MSP-1 and reduced malaria morbidity. In a number of studies, immunization with purified native MSP-1 or recombinant fragments of the protein has induced at least partial protection from the parasite (Diggs et al, 30 (1993) *Parasitol. Today* 9:300-302). Thus MSP-1 is an important target for the

development of a vaccine against *P. falciparum*.

MSP-1 is a 190-220 kDA glycoprotein. The C-terminal region has been the focus of recombinant production for use as a vaccine. However, a major problem in  
5 developing MSP-1 as a vaccine is the difficulty in obtaining recombinant proteins in bacterial or yeast expression systems that are equivalent in immunological potency to the affinity purified native protein (Chang et al., (1992) *J. Immunol.* 148:548-555.) and in large enough quantities to make vaccine production feasible.

10 Improved procedures for enhancing expression of sufficient quantities of MSP-1 would be advantageous.

BRIEF SUMMARY OF THE INVENTION

5       The present invention provides improved recombinant DNA compositions  
and procedures for increasing the mRNA levels and protein expression of the  
malarial surface antigen MSP-1 in cell culture systems, mammalian cell culture  
systems, or in transgenic mammals. The preferred protein candidate for expression  
in an expression system in accordance with the invention is a C-terminal derivative  
of MSP-1 having a DNA coding sequence with reduced AT content, and eliminated  
10   mRNA instability motifs and rare codons relative to the recombinant expression  
systems. Thus, in a first aspect, the invention provides a DNA sequence derived  
from the sequence shown in SEQ ID NO 2. This derivative sequence is shown in  
SEQ ID NO 1.

15       In a second aspect, the invention provides a process for preparing a modified  
nucleic acid of the invention comprising the steps of lowering the overall AT  
content of the natural gene encoding MSP-1, eliminating all mRNA instability  
motifs and replacing all rare codons with a preferred codon of the mammary gland  
tissue, all by replacing specific codons in the natural gene with codons recognizable  
to, and preferably preferred by mammary gland tissue and which code for the same  
20   amino acids as the replaced codon. This aspect of the invention further includes  
modified nucleic acids prepared according to the process of the invention.

      In a third aspect, the invention also provides vectors comprising modified  
MSP-1 nucleic acids of the invention and a goat beta casein promoter and signal  
sequence, and host cells transformed with nucleic acids of the invention.

25       In a fourth aspect, the invention provides transgenic non-human mammals  
whose germ lines comprise a nucleic acid of the invention.

      In a fifth aspect, the invention provides a DNA vaccine comprising a  
modified MSP-1 gene according to the invention.

DESCRIPTION OF THE DRAWINGS

Fig. 1 depicts the cDNA sequence of MSP-1<sub>42</sub> modified in accordance with the invention [SEQ ID NO 1] in which 306 nucleotide positions have been replaced to lower AT content and eliminate mRNA instability motifs while maintaining the same protein amino acid sequence of MSP-1<sub>42</sub>. The large letters indicate nucleotide substitutions.

Fig. 2 depicts the nucleotide sequence coding sequence of the "wild type" or native MSP-1<sub>42</sub> [SEQ ID NO 2].

Fig 3 is a codon usage table for wild type MSP-1<sub>42</sub> (designated "MSP wt" in the table) and the new modified MSP-1<sub>42</sub> gene (designated "edited MSP" in the table) and several milk protein genes (casein genes derived from goats and mouse). The numbers in each column indicate the actual number of times a specific codon appears in each of the listed genes. The new MSP-1<sub>42</sub> synthetic gene was derived from the mammary specific codon usage by first choosing GC rich codons for a given amino acid combined with selecting the amino acids used most frequently in the milk proteins.

Fig. 4a-c depict MSP-1<sub>42</sub> constructs GTC 479, GTC 564, and GTC 627, respectively as are described in the examples.

Fig. 5 panel A is a Northern analysis wherein construct GTC627 comprises the new MSP-1<sub>42</sub> gene modified in accordance with the invention, GTC479 is the construct comprising the native MSP-1<sub>42</sub> gene, and construct GTC469 is a negative control DNA.

Fig 5 panel B is a Western analysis wherein the eluted fractions after affinity purifications numbers are collected fractions. The results show that fractions from

GTC679 the modified MSP-1<sub>42</sub> synthetic gene construct reacted with polyclonal antibodies to MSP-1 and the negative control GTC479 did not.

Fig 6 depicts the nucleic acid sequences of OT1 [SEQ ID NO 3], OT2 [SEQ ID NO 4],  
5 MSP-8 [SEQ ID ON 5], MSP-2 [SEQ ID NO 6] and MSP1 [SEQ ID NO 7] described in the Examples.

Fig 7 is a schematic representation of plasmid BC574.

10 Fig 8 is a schematic representation of BC620.

Fig 9 is a schematic representation of BC670.

Fig 10 is a representation of a Western blot of MSP transgenic milk.  
15

Fig 11 is a schematic representation of the nucleotide sequence of MSP42-2 [SEQ ID NO 8].

Fig 12 is a schematic representation of the BC-718.  
20

Fig 13 is a representation of a Western blot of BC-718 expression in transgenic milk.

### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The issued US patents, 5 allowed applications, published foreign applications, and references cited herein are hereby incorporated by reference. Any conflicts between these references and the present disclosure shall be resolved in favor of the present disclosure.

The present invention provides improved recombinant DNA compositions 10 and procedures for increasing the mRNA levels and protein expression of the malarial surface antigen MSP-1 in cell culture systems, mammalian cell culture systems, or in transgenic mammals. The preferred protein candidate for expression in an expression system in accordance with the invention is a C-terminal derivative of MSP-1 having a DNA coding sequence with reduced AT content, and eliminated 15 mRNA instability motifs and rare codons relative to the recombinant expression systems. Thus, in a first aspect, the invention provides a DNA sequence derived from the sequence shown in SEQ ID NO 2. This derivative sequence is shown in SEQ ID NO 1.

In preferred embodiments, the nucleic acid of the invention is capable of 20 expressing MSP-1 in mammalian cell culture systems, or in transgenic mammals at a level which is at least 25%, and preferably 50% and even more preferably at least 100% or more of that expressed by the natural gene in mammalian cell culture systems, or in transgenic mammals under identical conditions.

As used herein, the term "expression" is meant mRNA transcription 25 resulting in protein expression. Expression may be measured by a number of techniques known in the art including using an antibody specific for the protein of interest. By "natural gene" or "native gene" is meant the gene sequence, or fragments thereof (including naturally occurring allelic variations), which encode the wild type form of MSP-1 and from which the modified nucleic acid is derived. 30 A "preferred codon" means a codon which is used more prevalently by the cell or

tissue type in which the modified MSP-1 gene is to be expressed, for example, in mammary tissue. Not all codon changes described herein are changes to a preferred codon, so long as the codon replacement is a codon which is at least recognized by the mouse mammary tissue. The term "reduced AT content" as used herein means having a lower overall percentage of nucleotides having A (adenine) or T (thymine) bases relative to the natural MSP-1 gene due to replacement of the A or T containing nucleotide positions or A and/or T containing codons with nucleotides or codons recognized by mouse mammary tissue and which do not change the amino acid sequence of the target protein.

10

In a second aspect, the invention provides a process for preparing a modified nucleic acid of the invention comprising the steps of lowering the overall AT content of the natural gene encoding MSP-1, eliminating all mRNA instability motifs and replacing all rare codons with a preferred codon of mammary gland tissue, all by replacing specific codons in the natural gene with codons recognizable to, and preferably preferred by mammary gland tissue and which code for the same amino acids as the replaced codon. Standard reference works describing the general principals of recombinant DNA technology include Watson, J.D. et al, *Molecular Biology of the Gene*, Volumes I and II the Benjamin/Cummings Publishing Company, Inc. publisher, Menlo Park, CA (1987) Darnell, J.E. et al., *Molecular Cell Biology*, Scientific American Books, Inc., Publisher, New York, NY (1986); Old, R.W., et al., *Principles of Gene Manipulation: An Introduction to Genetic Engineering*, 2d edition, University of California Press, publisher, Berkeley CA (1981); Maniatis, T., et al., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> ed. Cold Spring Harbor Laboratory, publisher, Cold Spring Harbor, NY (1989) and *Current Protocols in Molecular Biology*, Ausubel et al., Wiley Press, New York, NY (1992). This aspect of the invention further includes modified nucleic acids prepared according to the process of the invention.

20

25

Without being limited to any theory, previous research has indicated that a

conserved AU sequence (AUUUA) from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation (Shaw, G. and Kamen, R. *Cell* 46:659-667). The focus in the past has been on the presence of these instability motifs in the untranslated region of a gene. The instant invention is the first to recognize an advantage to eliminating the instability sequences in the coding region of the MSP-1 gene.

In a third aspect, the invention also provides vectors comprising modified MSP-1 nucleic acids of the invention and a goat beta casein promoter and signal sequence, and host cells transformed with nucleic acids of the invention.

In a fourth aspect, the invention provides transgenic non-human mammals whose germlines comprise a nucleic acid of the invention. General principals for producing transgenic animals are known in the art. See for example Hogan et al., *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory, (1986); Simons et al., *Bio/Technology* 6:179-183, (1988); Wall et al., *Biol. Reprod.* 32:645-651, (1985); Buhler et al., *Bio/Technology*, 8:140-143 (1990); Ebert et al., *Bio/Technology* 9:835-838 (1991); Krimerfort et al., *Bio/Technology* 9:844-847 (1991); Wall et al., *J.Cell. Biochem.* 49:113-120 (1992). Techniques for introducing foreign DNA sequences into mammals and their germ cells were originally developed in the mouse. See e.g., Gordon et al., *Proc. Natl. Acad. Sci. USA* 77:7380-7384, (1980); Gordon and Ruddle, *Science* 214: 1244-1246 (1981); Palmiter and Brinster, *Cell* 41: 343-345, 1985; Brinster et al., *Proc Natl. Acad Sci., USA* 82:4438-4442 (1985) and Hogan et al. (*ibid.*). These techniques were subsequently adapted for use with larger animals including cows and goats. Up until very recently, the most widely used procedure for the generation of transgenic mice or livestock, several hundred linear molecules of the DNA of interest in the form of a transgenic expression construct are injected into one of the pro- nuclei of a fertilized egg. Injection of DNA into the cytoplasm of a zygote is also widely used. Most recently cloning of an entire

transgenic cell line capable of injection into an unfertilized egg has been achieved (KHS Campbell et al., *Nature* 380 64-66, (1996)).

The mammary gland expression system has the advantages of high expression levels, low cost, correct processing and accessibility. Known proteins, such as bovine and human alpha-lactalbumin have been produced in lactating transgenic animals by several researchers. (Wright et al, *Bio/Technology* 9:830-834 (1991); Vilotte et al, *Eur. J. Biochem.*,186:43-48 (1989); Hochi et al., *Mol Reprod. And Devel.* 33:160-164 (1992); Soulier et al., *FEBS Letters* 297(1,2):13-18 (1992)) and the system has been shown to produce high levels of protein.

In a fifth aspect, the invention provides a DNA vaccine comprising a modified MSP-1 gene according to the invention. Such DNA vaccines may be delivered without encapsulation, or they may be delivered as part of a liposome, or as part of a viral genome. Generally, such vaccines are delivered in an amount sufficient to allow expression of the modified MSP-1 gene and to elicit an antibody response in an animal, including a human, which receives the DNA vaccine. Subsequent deliveries, at least one week after the first delivery, may be used to enhance the antibody response. Preferred delivery routes include introduction via mucosal membranes, as well as parenteral administration.

### Examples

#### *Creation of novel modified MSP-1<sub>42</sub> gene*

A novel modified nucleic acid encoding the C-terminal fragment of MSP-1 is provided. The novel, modified nucleic acid of the invention encoding a 42 kD C-terminal part of MSP-1 (MSP-1<sub>42</sub>) capable of expression in mammalian cells of the invention is shown in Fig. 1. The natural MSP-1<sub>42</sub> gene (Fig 2) was not capable of being expressed in mammalian cell culture or in transgenic mice. Analysis of the natural MSP-1<sub>42</sub> gene suggested several characteristics that distinguish it from

- mammalian genes. First, it has a very high overall AT content of 76%. Second, the mRNA instability motif, AUUUA, occurred 10 times in this 1100 bp DNA segment (Fig 2). To address these differences a new MSP-1<sub>42</sub> gene was designed. Silent nucleotide substitution was introduced into the native MSP-1<sub>42</sub> gene at 306
- 5 positions to reduce the overall AT content to 49.7%. Each of the 10 AUUUA mRNA instability motifs in the natural gene were eliminated by changes in codon usage as well. To change the codon usage, a mammary tissue specific codon usage table, Fig. 3a, was created by using several mouse and goat mammary specific proteins. The table was used to guide the choice of codon usage for the modified MSP-1<sub>42</sub> gene as
- 10 described above. For example as shown in the Table in Fig. 3a, in the natural gene, 65% (25/38) of the Leu was encoded by TTA, a rare codon in the mammary gland. In the modified MSP-1<sub>42</sub> gene, 100% of the Leu was encoded by CTG, a preferred codon for Leu in the mammary gland.
- 15 An expression vector was created using the modified MSP-1<sub>42</sub> gene by fusing the first 26 amino acids of goat beta-casein to the N-terminal of the modified MSP-1<sub>42</sub> gene and a SalI-Xho I fragment which carries the fusion gene was subcloned into the XhoI site of the expression vector pCDNA3. A His6 tag was fused to the 3' end of the MSP-1<sub>42</sub> gene to allow the gene product to be affinity purified. This resulted in
- 20 plasmid GTC627 (Fig.4c).

To compare the natural MSP-1<sub>42</sub> gene construct to the modified MSP-1<sub>42</sub> nucleic acid of the invention, an expression vector was also created for the natural MSP-1<sub>42</sub> gene and the gene was added to mammalian cell culture and injected into mice to

25 form transgenic mice as follows:

*Construction of the native MSP-1<sub>42</sub> Expression Vector*

To secrete the truncated merozoite surface protein-1 (MSP-1) of *Plasmodium falciparum*, the wild type gene encoding the 42KD C-terminal part of MSP-1 (MSP-1<sub>42</sub>) was fused to either the DNA sequence that encodes the first 15 or the first 26 amino acids of the goat beta-casein. This is achieved by first PCR amplify the MSP-1 plasmid (received from Dr. David Kaslow, NIH) with primers MSP1 and MSP2 (Fig. 6), then cloned the PCR product into the TA vector (Invitrogen). The BglII-XhoI fragments of the PCR product was ligated with oligos OT1 and OT2 (Fig. 6) into the expression vector pCDNA3. This yielded plasmid GTC564 (Fig.4b), which encodes the 15 amino acid beta- casein signal peptide and the first 11 amino acids of the mature goat beta-casein followed by the native MSP-1<sub>42</sub> gene. Oligos MSP-8 and MSP-2 (Fig. 6) were used to amplify MSP-1 plasmid by PCR, the product was then cloned into TA vector. The XhoI fragment was exercised and cloned into the XhoI site of the expression vector pCDNA3 to yield plasmid GTC479 (Fig.4a), which encoded 15 amino acid goat beta-casein signal peptide fused to the wild-type MSP-1<sub>42</sub> gene. A His6 tag was added to the 3' end of MSP-1<sub>42</sub> gene in GTC 564 and GTC 479.

#### *Native MSP-1<sub>42</sub> Gene Is Not Expressed In COS-7 Cells*

Expression of the native MSP gene in cultured COS-7 cells was assayed by transient transfection assays. GTC479 and GTC564 plasmids DNA were introduced into COS-7 cells by lipofectamine (Gibco-BRL) according to manufacturer's protocols. Total cellular RNA was isolated from the COS cells two days post-transfection. The newly synthesized proteins were metabolically labeled for 10 hours by adding <sup>35</sup>S methionine added to the culture media two days-post transfection.

To determine the MSP mRNA expression in the COS cells, a Northern blot was probed with a <sup>32</sup>P labeled DNA fragment from GTC479. No MSP RNA was detected in GTC479 or GTC564 transfectants (data not shown). Prolonged exposure revealed residual levels of degraded MSP mRNA. The <sup>35</sup>S labeled culture supernatants and

the lysates were immunoprecipitated with a polyclonal antibody raised against MSP. Immunoprecipitation experiments showed that no expression from either the lysates or the supernatants of the GTC479 or GTC564 transfected cells (data not shown). These results showed that the native MSP-1 gene was not expressed in COS  
5 cells.

*Native MSP-1<sub>42</sub> Gene is Not Expressed in the Mammary Gland of Transgenic Mice*

10

The SalI-XhoI fragment of GTC479, which encoded the 15 amino acids of goat beta-casein signal peptide, the first 11 amino acids of goat beta-casein, and the native MSP-1<sub>42</sub> gene, was cloned into the XhoI site of the beta-casein expressed in vector BC350. This yielded plasmid BC574 (Fig.7). A SalI-NotI fragment of BC574 was  
15 injected into the mouse embryo to generate transgenic mice. Fifteen lines of transgenic mice were established. Milk from the female founder mice was collected and subjected to Western analysis with polyclonal antibodies against MSP. None of the seven mice analyzed were found to express MSP-1<sub>42</sub> protein in their milk. To further determine if the mRNA of MSP-1<sub>42</sub> was expressed in the mammary gland,  
20 total RNA was extracted from day 11 lactating transgenic mice and analyzed by Northern blotting. No MSP-1<sub>42</sub> mRNA was detected by any of the BC 574 lines analyzed. Therefore, the MSP-1<sub>42</sub> transgene was not expressed in the mammary gland of transgenic mice. Taken together, these experiments suggest that native parasitic MSP-1<sub>42</sub> gene could not be expressed in mammalian cells, and the block is  
25 as the level of mRNA abundance.

*Expression of MSP in the Mammalian Cells*

Transient transfection experiments were performed to evaluate the expression of

the modified MSP-1<sub>42</sub> gene of the invention in COS cells. GTC627 and GTC479 DNA were introduced into the COS-7 cells. Total RNA was isolated 48 hours post-transfection for Northern analysis. The immobilized RNA was probed with <sup>32</sup>P labeled SalI-XhoI fragment of GTC627. A dramatic difference was observed between GTC479 and GTC627. While no MSP-1<sub>42</sub> mRNA was detected in the GTC479 transfected cells as shown previously, abundant MSP-1<sub>42</sub> mRNA was expressed by GTC627 (Fig. 5, Panel A). GTC 469 was used as a negative control and comprises the insert of GTC564 cloned into cloning vector PU19, a commercially available cloning vector. A metabolic labeling experiment with <sup>35</sup>S methionine followed by immunoprecipitation with polyclonal antibody (provided by D. Kaslow NIAID, NIH) against MSP showed that MSP-1<sub>42</sub> protein was synthesized by the transfected COS cells (Fig.5, Panel B). Furthermore, MSP-1<sub>42</sub> was detected in the transfected COS supernatant, indicating the MSP-1<sub>42</sub> protein was also secreted. Additionally, using Ni-NTA column, MSP-1<sub>42</sub> was affinity purified from the GTC627 transfected COS supernatant.

These results demonstrated that the modification of the parasitic MSP-1<sub>42</sub> gene lead to the expression of MSP mRNA in the COS cells. Consequently, the MSP-1<sub>42</sub> product was synthesized and secreted by mammalian cells.

Polyclonal antibodies used in this experiment may also be prepared by means well known in the art (*Antibodies: A Laboratory Manual*, Ed Harlow and David Lane, eds. Cold Spring Harbor Laboratory, publishers (1988)). Production of MSP serum antibodies is also described in Chang et al., *Infection and Immunity* (1996) 64:253-261 and Chang et al., (1992) *Proc Natl. Acad. Sci. USA* 86:6343-6347.

The results of this analysis indicate that the modified MSP-1<sub>42</sub> nucleic acid of the invention is expressed at a very high level compared to that of the natural protein

which was not expressed at all. These results represent the first experimental evidence that reducing the AT % in a gene leads to expression of the MSP gene in heterologous systems and also the first evidence that removal of AUUUA mRNA instability motifs from the MSP coding region leads to the expression of MSP protein in COS cells. The results shown in Fig. 5, Panel A Northern (i.e. no RNA with native gene and reasonable levels with a modified DNA sequence in accordance with the invention), likely explains the increase in protein production.

The following examples describe the expression of MSP1-42 as a native non-fusion (and non-glycosylated) protein in the milk of transgenic mice.

#### *Construction of MSP Transgene*

To fuse MSP1-42 to the 15 amino acid  $\beta$ -casein signal peptide, a pair of oligos, MSP203 and MSP204 (MSP203: ggccgctcgcagccaccatgaaggctccataattgcc tctcgggtggctcggccattgcagccgctcctccctccat, MSP204: cgatgacggaggagtgacggctg caatggccagagccaccagacaggcaattatgaggaccttcatggctggctcgcagc). which encode the 15 amino acid - casein signal and the first 5 amino acid of the MSP1-42 ending at the Cla I site, was ligated with a Cla I-Xho I fragment of BC620 (Fig. 8) which encodes the rest of the MSP1-42 gene, into the Xho I site of the expression vector pCDNA3. A Xho I fragment of this plasmid (GTC669) was then cloned into the Xho I site of milk specific expression vector BC350 to generate B670 (Fig.9)

#### *Expression of MSP1-42 in the milk of transgenic mice*

A Sal I-Not I fragment was prepared from plasmid BC670 and microinjected into the mouse embryo to generate transgenic mice. Transgenic mice was identified by extracting mouse DNA from tail biopsy followed by PCR analysis using oligos GTC17 and MSP101 (sequences of oligos: GTC17, GATTGACAAGTAATACGCTGTTTCCTC. Oligo MSP101, GGATTCAATAGATACGG). Milk from the female founder transgenic mice was collected at day 7 and day 9 of lactation, and subjected to western analysis to determine the expression level of MSP-1-42 using an polyclonal anti-MSP antibody and monoclonal anti MSP antibody 5.2 (Dr. David Kaslow, NIH). Results indicated that the level of MSP-1-42 expression in the milk of

transgenic mice was at 1-2 mg/ml (Fig. 10).

*Construction of MSP1-42 glycosylation sites minus mutants*

5 Our analysis of the milk produced MSP revealed that the transgenic MSP protein was N-glycosylated. To eliminate the N-glycosylation sites in the MSP1-42 gene, Asn. (N) at positions 181 and 262 were substituted with Gln.(Q). The substitutions were introduced by designing DNA oligos that anneal to the corresponding region of MSP1 and carry the AAC to CAG mutations. These oligos were then used as PCR primers to produce DNA fragments that  
10 encode the N to Q substitutions.

To introduce N262-Q mutation, a pair of oligos, MSPGYLYCO-3 (CAGGGAATGCTGCAGATCAGC) AND MSP42-2 (AATTCTCGAGTTAGTG GTGGTGGTGGTGGTGATCGCAGAAAATACCATG, FIG. 11), were used to PCR amplify  
15 plasmid GTC627, which contains the synthetic MSP1-42 gene. The PCR product was cloned into pCR2.1 vector (Invitrogen). This generated plasmid GTC716.

To introduce N181-Q mutation, oligos MSPGLYCO-1 (CTCCTTGTTTCAGG AACTTGTAGGG) and MSPGLCO-2 (GTCCTGCAGTACACATATGAG, Fig 4) were used to  
20 amplify plasmid GTC 627. The PCR product was cloned into pCR2.1. This generated plasmid GTC700.

The MSP double glycosylation mutant was constructed by the following three steps: first, a Xho I-Bsm I fragment of BC670 and the Bsm I-Xho I fragment of GTC716 is ligated into the  
25 Xho I site of vector pCR2.1. This resulted a plasmid that contain the MSP-1-42 gene with N262-Q mutation. EcoN I-Nde I fragment of this plasmid was then replaced by the EcoN I-Nde I fragment from plasmid GTC716 to introduce the second mutation, N181-Q. A Xho I fragment of this plasmid was finally cloned into BC350 to generate BC718 (Fig. 12).

30 *Transgenic expression of nonglycosylated MSP-1*

BC718 has the following characteristics: it carries the MSP1-42 gene under the control of the  $\beta$ -casein promoter so it can be expressed in the mammary gland of the transgenic animal during lactation. Further, it encodes a 15 amino acid  $\beta$ -casein leader sequence fused directly to MSP1-42.

so that the MSP1-42, without any additional amino acid at its N-terminal, can be secreted into the milk. Finally, because the N-Q substitutions, the MSP produced in the milk of the transgenic animal by this construct will not be N-glycosylated. Taken together, the transgenic MSP produced in the milk by BC718 is the same as the parasitic MSP.

- 5        A SalI/XhoI fragment was prepared from plasmid BC718 and microinjected into mouse embryos to generate transgenic mice. Transgenic animals were identified as described previously. Milk from female founders was collected and analyzed by Western blotting with antibody 5.2. The results, shown in Figure 13, indicate expression of nonglycosylated MSP1 at a concentration of 0.5 to 1 mg/ml.

What is claimed is:

1. A modified MSP-1 nucleic acid sequence, as shown in SEQ ID NO 1.
- 5 2. A process for preparing a modified MSP-1 nucleic acid comprising the steps of lowering the overall AT content of the natural gene encoding MSP-1, eliminating all mRNA instability motifs and replacing all rare codons with a preferred codon of the mouse mammary gland.
- 10 3. A modified MSP-1 nucleic acid prepared by the process according to claim 2.
4. A vector comprising a modified MSP-1 nucleic acid according to claim 1 and a goat beta casein promoter and signal sequence.
- 15 5. A host cell transformed with the vector according to claim 4.
6. A transgenic non-human mammal comprising a vector according to claim 4.
7. A transgenic non-human mammal comprising a modified MSP-1 nucleic  
20 acid according to claim 1.
8. A DNA vaccine comprising a modified nucleic acid according to claim 1.

C

Fig. 1

1 ccCgtCactccCtccgtCa gataacatCctGtcCaaGatCgaGaaGaaGta ~:  
 1>AlaValThrProSerValIleAspAsnIleLeuSerLysIleGluAsnGluTyrG  
 56 AGGTGCTGtACCTGAAgocCTGgcaggGgtCtaCCGgagCCTGAAgaaGaaG  
 19>IuValLeuTyrLeuLysProLeuAlaGlyValTyrArgSerLeuLysLysGln  
 109 CtGaaGaaCAacgtGatGacCttCaaCgtGaaCgtGaaggatATCCTGaaCAGC  
 37>LeuGluAsnAsnValMetThrPheAsnValAsnValLysAspIleLeuAsnSer  
 163 CGGTTCAAaaGogGgaGaaCttCAAgaacgtCTGgaGAGCGATCtGatCoc  
 55>ArgPheAsnLysArgGluAsnPheLysAsnValLeuGluSerAspLeuIlePr  
 216 CtaCaaGgatCtGacCAGCAGCaaCtaCgtGgtCAAgaatCCtaCaaGttCC  
 72>oTyrLysAspLeuThrSerSerAsnTyrValValLysAspProTyrLysPheL  
 269 TGAaCaaGaaGaaGAGAGATAAGttCtGAGCAGTTAACTaCaaCaaGAGGATAG  
 90>euAsnLysGluLysArgAspLysPheLeuSerSerTyrAsnTyrIleLysAspSe  
 324 CATTGATACGATATCAACTTCCaaCgaatGtCctGGGATACTaCaaGatCCT  
 108>rIleAspThrAspIleAsnPheAlaAsnAspValLeuGlyTyrTyrLysIleLe  
 378 GtccgaGaaGtaCaaGAGCGATCtGatTCAATCaaGaaGtaCaaCAAGATAA  
 126>uSerGluLysTyrLysSerAspLeuAspSerIleLysLysTyrIleAsnAspLy  
 432 GCAggGaaGaaCGAGAAgtacCtGccCTTCTGAACAACTCGAGACCCTGTA  
 144>sGlnGlyGluAsnGluLysTyrLeuProPheLeuAsnAsnIleGluThrLeuTy  
 486 CAAgacCgtCaaCGATAAGATTGATCtGttCgtGATCcaCCTGgaGocCaaGgt  
 162>rLysThrValAsnAspLysIleAspLeuPheValIleHlsLeuGluAlaLysVa  
 NdeI  
 540 CCTGAACTACATATGAGAAgAGCAACGTGgaGgtCaaGatCaaGaaGctGaa  
 180>ILeuAsnTyrThrTyrGluLysSerAsnValGluValLysIleLysGluLeuAs  
 594 TTACCTGAAgacCaaCaaGaaTAACTGGCgGATTTCAAgaGaaCAACAACTT  
 198>nTyrLeuLysThrIleGlnAspLysLeuAlaAspPheLysLysAsnAsnAsnPh  
 648 CGTGGGATCgcGatCtGAGCACGATTAaACCAaaCAACCTGCTGACaa  
 216>eValGlyIleAlaAspLeuSerThrAspTyrAsnHlsAsnAsnLeuLeuThrLy  
 702 GTTCCTGAGCacCGGTATGGTCTTGAaaaaCctGgcCaaGacCGTCTGAGCAA  
 234>sPheLeuSerThrGlyMetValPheGluAsnLeuAlaLysThrValLeuSerAs  
 756 CCTGCTGgatGGGaaCtGcaGggGatGctGaACATCAGCcaGcACCAgtGTGT  
 252>nLeuLeuAspGlyAsnLeuGlnGlyMetLeuAsnIleSerGlnHisGlnCysVa  
 810 GAAgaaGaaGtGTCCCAaaCAGCGGgtGTTTCAGACACTGgatGAGAGAGA  
 270>IlysLysGlnCysProGlnAsnSerGlyCysPheArgHlsLeuAspGluArgG  
 864 GGAgtGTAAgtGTCTGCTGaaCTACAAgaGaaAGGTGATAAGtGTGTGAAAAAC  
 288>uGluCysLysCysLeuLeuAsnTyrLysGlnGluGlyAspLysCysValGluAsn  
 919 CCaaTCCTACTTGTAAACGAaaCAATGGTGGATGTGATGCCGATGCCAAgtGTACCG  
 307>ProAsnProThrCysAsnGluAsnAsnGlyGlyCysAspAlaAspAlaLysCysThrG  
 977 aGGAAGATTcAGGgAGCAACCGgaGaaGATCACCTGTGAgtGTACCAAGCTGATT  
 326>IuGluAspSerGlySerAsnGlyLysLysIleThrCysGluCysThrLysProAspS  
 1034 CTTATCCACTGTTCGATGGTATCTTCTGTAGT  
 345>erTyrProLeuPheAspGlyIlePheCysSer

F16.2

1 GCAGTAACCTCTCCGTAATT .AACATACTTTCTAAAAATTGAAAATGAATA\*  
1> AlaValThrProSerValIle AsnIleLeuSerLysIleGluAsnGluTyr  
EcoNI (73)  
56 AGGTTTATATTTAAAACTTTAGCAGGTGTTTATAGAAGTTTAAAAAACAATT  
191 uValLeuTyrLeuLysProLeuAlaGlyValTyrArgSerLeuLysLysGlnLe  
111 AGAAAATAACGTTATGACATTTTAATGTTAATGTTAAGGATATTTTAAATTCACGA  
37> uGluAsnAsnValMetThrPheAsnValAsnValLysAspIleLeuAsnSerArg  
166 TTTAATAAACGCGTAAAAATTTCAAAATGTTTTAGAATTCAGATTTAATTCATATA  
56> PheAsnLysArgGluAsnPheLysAsnValLeuGluSerAspLeuIleProTyrL  
221 AAGATTTAACATCAAGTAATTATGTTGTCAGAGATCCATATAAATTTCTTAATAA  
74> yAspLeuThrSerSerAsnTyrValValLysAspProTyrLysPheLeuAsnLy  
276 AGAAAAAAGAGATAAATCTCTTAACAGCTTATAATTATTAAGGATCAATAGAT  
92> sGluLysArgAspLysPheLeuSerSerTyrAsnTyrIleLysAspSerIleAsp  
331 ACGGATATAAATTTTGCAATGATGTTCTTGATATTATAAAATATTATCCGAAA  
111> ThrAspIleAsnPheAlaAsnAspValLeuGlyTyrTyrLysIleLeuSerGluL  
386 AATATAAATCAGATTTAGATTTCAATTAATAAATATATCAACGACAAACAAGGTGA  
129> yTyrLysThrSerAspLeuAspSerIleLysLysTyrIleAsnAspLysGlnGlyG  
441 AATAGAGAAATACCTTCCTTTTAAACAATTTAGAGACTTATATAAAACAGTT  
147> uAsnGluLysTyrLeuProPheLeuAsnAsnIleGluThrLeuTyrLysThrVal  
496 AATGATAAAATTCATTTATTGTAATTCATTTAGAAGCAAAAGTTCTAAATTTATA  
166> AsnAspLysIleAspLeuPheValIleHisLeuGluAlaLysValLeuAsnTyrT  
551 CATATGAGAAATCAACGTAGAAGTTAAAAATAAAGAAGCTTAATTTACTTAAAAAC  
184> hrTyrGluLysSerAsnValGluValLysIleLysGluLeuAsnTyrLeuLysTh  
606 AATTCAAGACAAATTCGCAGATTTTAAAAAATAACAATTTTCGTTGGAAATTCGT  
202> rIleGlnAspLysLeuAlaAspPheLysLysAsnAsnAsnPheValGlyIleAla  
661 GATTTATCAACAGATTTATAACCAATAAATCTTATGACAAAGTTCCCTTAGTACAG  
221> AspLeuSerThrAspTyrAsnHisAsnAsnLeuLeuThrLysPheLeuSerThrG  
716 GTATGGTTTTTGAATACTTGCTAAAAACCGTTTTTATCTAATTTCTGATGAAA  
239> lYMetValPheGluAsnLeuAlaLysThrValLeuSerAsnLeuLeuAspGlyAs  
771 CTGCAAGGTATGTTAAACATTTCAACAACCAATGCGTAAAAAACAATGTCCA  
257> nLeuGlnGlyMetLeuAsnIleSerGlnHisGlnCysValLysLysGlnCysPro  
826 CAAAATTCCTGGATGTTTCAGACATTTAGATGAAGAAGAAGATGAAATTTTAT  
276> GlnAsnSerGlyCysPheArgHisLeuAspGluArgGluGluCysLysCysLeuL  
881 TAAATTACAAACAGAAGGTGATAAATGTGTTGAAAAATCCAAATCTCTACTTGTA  
294> euAsnTyrLysGlnGluGlyAspLysCysValGluAsnProAsnProThrCysAs  
936 CGAAAATAATGGTGGATGTGATGCAGATGCCAAATGTACCGAAGAAGATTCAGGT  
312> nGluAsnAsnGlyGlyCysAspAlaAspAlaLysCysThrGluGluAspSerGly  
991 AGCAACGGAAAGAAAATCAGATGTGAATGTACTAAACCTGATTCTTATCCACTTT  
331> SerAsnGlyLysLysIleThrCysGluCysThrLysProAspSerTyrProLeuP  
PstI (1059)  
1046 TCGATGGTATTTTCTGCGAGTCACCAACCACCACCACCACTAATC  
349> heAspGlyIlePheCysSerHisHisHisHisHisHisHis...

Fig. 3A

| Codon | AA  | post b-case | post K-case | SP wt | Edited MSP | mouse b-case | mouse a-case | mouse | 12hr | mouse e-case |
|-------|-----|-------------|-------------|-------|------------|--------------|--------------|-------|------|--------------|
| TTT   | Phe | 5           | 4           | 8     | 0          | 4            | 8            |       | 3    | 4            |
| TTT   | Phe | 4           | 3           | 7     | 15         | 4            | 8            |       | 7    | 1            |
| TTA   | Leu | 0           | 2           | 25    | 0          | 0            | 0            |       | 0    | 0            |
| TTG   | Leu | 0           | 2           | 3     | 0          | 0            | 0            |       | 0    | 1            |
| TCT   | Ser | 5           | 1           | 4     | 1          | 13           | 5            |       | 7    | 5            |
| TCC   | Ser | 2           | 2           | 2     | 3          | 8            | 14           |       | 8    | 2            |
| TCA   | Ser | 1           | 4           | 10    | 1          | 1            | 3            |       | 2    | 0            |
| TGG   | Ser | 0           | 1           | 0     | 0          | 0            | 0            |       | 0    | 0            |
| TAT   | Tyr | 2           | 7           | 17    | 2          | 1            | 3            |       | 2    | 1            |
| TAC   | Tyr | 1           | 2           | 3     | 18         | 2            | 8            |       | 6    | 7            |
| TAA   | *** | 1           | 2           | 0     | 0          | 1            | 0            |       | 1    | 0            |
| TAG   | *** | 0           | 0           | 0     | 0          | 0            | 0            |       | 0    | 0            |
| TGT   | Cys | 1           | 1           | 10    | 12         | 0            | 0            |       | 0    | 0            |
| TGC   | Cys | 0           | 2           | 2     | 0          | 2            | 2            |       | 2    | 1            |
| TGA   | *** | 0           | 0           | 0     | 0          | 0            | 1            |       | 0    | 1            |
| TGG   | Trp | 1           | 1           | 0     | 0          | 0            | 2            |       | 2    | 2            |
| CTT   | Leu | 9           | 1           | 9     | 0          | 18           | 9            |       | 3    | 3            |
| CTC   | Leu | 5           | 2           | 0     | 0          | 7            | 8            |       | 0    | 1            |
| CTA   | Leu | 1           | 2           | 1     | 0          | 1            | 2            |       | 1    | 0            |
| CTG   | Leu | 11          | 5           | 0     | 38         | 10           | 17           |       | 4    | 1            |
| CCT   | Pro | 17          | 6           | 4     | 2          | 8            | 6            |       | 3    | 0            |
| CCC   | Pro | 12          | 0           | 1     | 6          | 8            | 8            |       | 6    | 4            |
| CCA   | Pro | 3           | 13          | 5     | 1          | 5            | 8            |       | 2    | 2            |
| CCG   | Pro | 1           | 1           | 0     | 1          | 0            | 0            |       | 0    | 1            |
| CAT   | His | 0           | 1           | 3     | 0          | 2            | 8            |       | 2    | 1            |
| CAC   | His | 5           | 3           | 1     | 4          | 4            | 0            |       | 3    | 0            |
| CAA   | Gln | 5           | 9           | 9     | 0          | 9            | 21           |       | 9    | 7            |
| CAG   | Gln | 18          | 6           | 0     | 9          | 21           | 32           |       | 12   | 8            |
| CGT   | Arg | 0           | 1           | 1     | 0          | 0            | 0            |       | 0    | 0            |
| CGC   | Arg | 0           | 0           | 0     | 0          | 1            | 0            |       | 0    | 0            |
| CGA   | Arg | 0           | 0           | 1     | 0          | 0            | 0            |       | 0    | 1            |
| CGG   | Arg | 1           | 0           | 0     | 3          | 0            | 0            |       | 0    | 0            |
| ATT   | Ile | 4           | 5           | 13    | 0          | 3            | 4            |       | 3    | 4            |
| ATC   | Ile | 6           | 3           | 2     | 20         | 7            | 5            |       | 8    | 5            |
| ATA   | Ile | 1           | 3           | 5     | 0          | 1            | 0            |       | 2    | 0            |
| ATG   | Met | 7           | 3           | 3     | 3          | 4            | 12           |       | 2    | 13           |
| ACT   | Thr | 7           | 6           | 3     | 2          | 6            | 5            |       | 1    | 4            |
| ACC   | Thr | 2           | 7           | 3     | 13         | 4            | 4            |       | 4    | 4            |
| ACA   | Thr | 2           | 4           | 9     | 1          | 1            | 1            |       | 2    | 0            |
| ACG   | Thr | 0           | 0           | 1     | 0          | 0            | 0            |       | 2    | 0            |
| AAT   | Asn | 2           | 6           | 29    | 3          | 4            | 6            |       | 3    | 1            |
| AAC   | Asn | 2           | 3           | 12    | 38         | 4            | 9            |       | 4    | 6            |
| AAA   | Lys | 7           | 6           | 38    | 0          | 6            | 7            |       | 3    | 5            |
| AAG   | Lys | 6           | 4           | 4     | 42         | 3            | 6            |       | 13   | 7            |
| AGT   | Ser | 2           | 6           | 5     | 2          | 3            | 6            |       | 6    | 3            |
| AGC   | Ser | 5           | 0           | 2     | 16         | 2            | 8            |       | 8    | 3            |
| AGA   | Arg | 2           | 2           | 4     | 3          | 1            | 8            |       | 1    | 1            |
| AGG   | Arg | 0           | 2           | 0     | 0          | 0            | 0            |       | 0    | 1            |
| GTT   | Val | 5           | 6           | 15    | 0          | 7            | 4            |       | 2    | 3            |
| GTC   | Val | 8           | 2           | 1     | 11         | 7            | 3            |       | 3    | 0            |
| GTA   | Val | 2           | 2           | 5     | 0          | 2            | 4            |       | 1    | 3            |
| GTG   | Val | 8           | 4           | 0     | 10         | 8            | 3            |       | 5    | 3            |
| GCT   | Ala | 1           | 3           | 2     | 0          | 8            | 17           |       | 4    | 2            |
| GCC   | Ala | 4           | 7           | 1     | 8          | 6            | 3            |       | 3    | 3            |
| GCA   | Ala | 3           | 7           | 6     | 1          | 4            | 13           |       | 1    | 1            |
| GCG   | Ala | 0           | 1           | 0     | 0          | 0            | 0            |       | 0    | 0            |
| GAT   | Asp | 4           | 5           | 25    | 27         | 3            | 6            |       | 4    | 2            |
| GAC   | Asp | 0           | 2           | 2     | 0          | 1            | 2            |       | 1    | 3            |
| GAA   | Glu | 10          | 6           | 21    | 31         | 6            | 12           |       | 9    | 6            |
| GAG   | Glu | 9           | 5           | 4     | 22         | 5            | 5            |       | 5    | 5            |
| GGT   | Gly | 2           | 1           | 8     | 4          | 0            | 0            |       | 0    | 0            |
| GGC   | Gly | 0           | 0           | 0     | 0          | 0            | 0            |       | 0    | 0            |
| GGA   | Gly | 2           | 1           | 6     | 3          | 1            | 0            |       | 1    | 0            |
| GGG   | Gly | 1           | 0           | 0     | 7          | 1            | 0            |       | 0    | 0            |

Fig. 4A





Fig. 4B







FIG. 5




Panel A

Panel B

TAAGTCGAGCGAACCATGAAGGTCCTCATCCTTGCCCTGTCTGGTGGCTCTGG  
CCATTGCA

011520

FIG. 7






Diagram of BC620

FIGURE 8





FIGURE 9



**Western Analysis of MSP transgenic milk.**  
Lane 1, Molecular weight marker; lane 2, nontransgenic mice milk; lane 3, milk from BC628-146 transgenic mouse; lane 4-9, milk from BC670 transgenic mice. The blot was reacted with monoclonal antibody 5.2 against MSP.

**FIGURE 10**

FIGURE 11




FIGURE 12

FIGURE 13

